Kringle Pharma (TSE:4884) Shares Outstanding (EOP): 7.40 Mil (As of Mar. 2026)


TSE:4884 Kringle Pharma Inc TSE:4884
44 GF Score
Price 円340.00
GF Value 円494.49
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Kringle Pharma Shares Outstanding (EOP)?

Kringle Pharma TSE:4884 +1.19% 44 Shares Outstanding (EOP) is 7.40 Mil as of Mar. 2026. GuruFocus rates TSE:4884 with a GF Score™ of 44/100 and a GF Value™ of 円494.49 (Possible Value Trap). The stock has 5 warning signs investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Kringle Pharma's shares outstanding for the quarter that ended in Mar. 2026 was 7.40 Mil.

Kringle Pharma's quarterly shares outstanding increased from Dec. 2025 (7.26 Mil) to Mar. 2026 (7.40 Mil). It means Kringle Pharma issued new shares from Dec. 2025 to Mar. 2026 .

Kringle Pharma's annual shares outstanding increased from Sep. 2024 (6.81 Mil) to Sep. 2025 (7.02 Mil). It means Kringle Pharma issued new shares from Sep. 2024 to Sep. 2025 .


Kringle Pharma  (TSE:4884) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Kringle Pharma Shares Outstanding (EOP) Related Terms


Kringle Pharma Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Kringle Pharma's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kringle Pharma Shares Outstanding (EOP) Chart

Kringle Pharma Annual Data
Trend Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Shares Outstanding (EOP)
Get a 7-Day Free Trial 4.34 5.38 5.52 6.81 7.02

Kringle Pharma Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Mar25 Jun25 Sep25 Dec25 Mar26
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.84 6.84 7.02 7.26 7.40

TSE:4884 vs VRTX, REGN, ALNY: Shares Outstanding (EOP) Comparison

For the Biotechnology subindustry, Kringle Pharma's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kringle Pharma Shares Outstanding (EOP) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kringle Pharma's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Kringle Pharma's Shares Outstanding (EOP) falls into.


TSE:4884
44GF Score
Kringle Pharma Inc TSE:4884
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kringle Pharma Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 7.40 Mil mean?
Kringle Pharma (TSE:4884) has a Shares Outstanding (EOP) of 7.40 Mil as of Mar. 2026. The total shares a company has outstanding, at period-end. View historical data on Kringle Pharma and its competitors.
Is Kringle Pharma's Shares Outstanding (EOP) too high?
Kringle Pharma's current Shares Outstanding (EOP) is 7.40 Mil. Overall, Kringle Pharma has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Kringle Pharma's Shares Outstanding (EOP) compare to VRTX and REGN?
Kringle Pharma's Shares Outstanding (EOP) of 7.40 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Kringle Pharma and its competitors. Kringle Pharma's current Shares Outstanding (EOP) is 7.40 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kringle Pharma stock overvalued right now?
Based on GuruFocus' analysis, Kringle Pharma (TSE:4884) is currently considered Possible Value Trap. The stock's GF Value™ is 円494.49, compared to a current price of 円340.00 — trading 31.2% below its estimated fair value. The current Shares Outstanding (EOP) is 7.40 Mil. Kringle Pharma's overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Kringle Pharma (TSE:4884), the current Shares Outstanding (EOP) is 7.40 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kringle Pharma (TSE:4884) Overvalued in 2026?

Based on GuruFocus' analysis, Kringle Pharma stock appears to be undervalued. The current stock price of 円340.00 is trading 31.2% below its estimated GF Value™ of 円494.49. GuruFocus considers Kringle Pharma to be Possible Value Trap.

Key valuation signals for TSE:4884:

  • Shares Outstanding (EOP): 7.40 Mil
  • GF Value™: 円494.49 vs. price of 円340.00 (31.2% below fair value)
  • GF Score™: 44/100 with 5 warning signs

No single metric tells the full story. See the TSE:4884 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Kringle Pharma Business Description

Address 7-7-15 Saito asagi, 207 Saito Bio-Incubator, Osaka Prefecture, Ibaraki, JPN, 567-0085
Kringle Pharma Inc is engaged in the research and development of HGF (hepatocyte growth factor) protein as a therapeutic agent for intractable diseases. The Company operates in a single segment, pharmaceutical development.
44GF Score

Get the complete analysis for TSE:4884

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円340.00
Price
円494.49
GF Value